Article
The association of efficacy with PD-1/PD-L1 inhibition and tumor mutational burden in advanced nonsmall cell lung cancer: A PRISMA-guided literature review and meta-analysis.
Medicine - 22 Jul 2022
Yu Dahui, Yuan Chong, Zhang Hedan, Chu Wenyan
Abstract excerpt
BACKGROUND: Tumor mutation burden (TMB) has been reported to emerge as an independent biomarker of response to identify patients who would achieve benefit from immune checkpoint inhibitors. However, it still remains controversy that whether TMB can be a robust biomarker of response to programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibition. We performed this meta-analysis to assess the relationship...
Topics
- B7-H1 Antigen
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Humans
- Immune Checkpoint Inhibitors
- Lung Neoplasms
- Mutation
- Programmed Cell Death 1 Receptor